{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.8","upperLimit":"97.5","value":"96.65"},{"groupId":"OG001","lowerLimit":"95.9","upperLimit":"98.2","value":"97.05"},{"groupId":"OG002","lowerLimit":"94.9","upperLimit":"97.6","value":"96.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1734"},{"groupId":"OG001","value":"868"},{"groupId":"OG002","value":"866"}],"units":"Participants"}],"description":"OS time is defined as time from enrollment to death or date of last contact for patients who are alive. 5-year OS will be estimated for the two randomized arms using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Non-DS HR B-ALL patients","id":"OG000","title":"Non-DS HR B-ALL Overall"},{"description":"Non-DS HR patients receive post induction age-adjusted intrathecal (IT) methotrexate (MTX)","id":"OG001","title":"Non-DS HR B-ALL Arm A"},{"description":"Non-DS HR patients receive post-Induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone","id":"OG002","title":"Non-DS HR B-ALL Arm B"}],"paramType":"NUMBER","populationDescription":"Total HR B-ALL patients (includes patients from AALL0932). Inevaluable and ineligible patients were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"At 5 years","title":"Overall Survival (OS) Rate for HR B-ALL Patients, Overall and by Randomized Arm","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}